The preeminent role of Farxiga (dapagliflozin) in heart failure (HF) has been given a boost by new long-term data presented at the annual meeting of the Europea 23 May 2023
Positive Phase III results for Sanofi’s trailblazing biologic Dupixent (dupilumab) could open up a significant opportunity in a new treatment setting. 22 May 2023
New real-world data for the newly-approved schizophrenia med Uzedy (risperidone) have been presented at the annual meeting of the Schizophrenia International Re 15 May 2023
Spanish skincare specialist Almirall has announced results from a new secondary analysis using data from the Phase III ADvocate and ADhere studies of lebrikizum 2 May 2023
Post-marketing research into Vabysmo (faricimab) shows superior performance to aflibercept in wet age-related macular degeneration (nAMD). 26 April 2023
Merck & Co has announced results from the KEYNOTE-966 trial of Keytruda (pembrolizumab) alongside chemotherapy (gemcitabine and cisplatin) for the first-line tr 17 April 2023
Roche has announced new data from the Phase III IMbrave050 study, combining Tecentriq (atezolizumab) and Avastin (bevacizumab), at the American Association for 17 April 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.